Guggenheim - Truenewj

Guggenheim just got a buy rating on StubHub. Bets with a .50 price target on the rise of live events

Guggenheim just got a buy rating on StubHub. Bets with a $12.50 price target on the rise of live events

amefika3 weeks ago04 mins

Quick reading Guggenheim initiated coverage of StubHub (STUB) with a Buy rating and a $12.50 price target, betting on enduring demand for live events and tailwinds in global ticket sales. StubHub’s swinging first-quarter profitability and EBITDA growth of 50% support the bullish case, although risks from high leverage and consumer confidence warrant careful position sizing….

Guggenheim reaffirmed its purchase of GeneDx in late October and raised the price target to 0 after outperforming the third quarter

Guggenheim reaffirmed its purchase of GeneDx in late October and raised the price target to $170 after outperforming the third quarter

amefika7 months ago02 mins

GeneDx Holdings Corp. (NASDAQ:WGS) is one of the The best digital health stocks to buy now. On October 29, 2025, Guggenheim raised GeneDx (NASDAQ:WGS) to a price target of $170 (Buy) following the company’s dramatic third-quarter announcement a day earlier. GeneDx had just reported revenue of $116.7 million, up 52% year-over-year and roughly ~12% ahead…